Targeting inflammasomes for therapies

1,2,3-trichloropropane (TCP) is an emerging groundwater contaminant that is present in widely-used soil fumigants. Individual states have or are in the process of developing regulatory levels for TCP that are as low as 0.0005 micrograms per litre (µg/L). Remedial technologies for TCP that have been implemented at scales ranging from laboratory treatability studies to full-scale field implementation include in situ bioremediation (ISB) and in situ chemical reduction (ISCR).

During this educational webinar, Dr. Timothy A. Hacker discusses strategies and experimental design of long-term, chronic cardiovascular research in rodents. Specifically, he reviews the use of implantable telemetry, imaging and complimentary technologies for cardiovascular research, highlighting when to adopt one technology versus another and the advantages and limitations of each. He shares best-practices related to data acquisition and analysis, data interpretation and how to prepare data in support of your research hypothesis.

The potential of gene editing as a therapeutic has come to fruition in the past several years, as clinical data from various studies has shown very positive results.

The Webinar will focus on how health sciences are becoming more democratized and decentralized, hacking biotechnology investments is getting more accessible, obvious, and transparent. Investing in biotech is no longer reserved for specialized VCs and funds with deep pockets. This one hour webinar will discuss finding the right opportunities in responsible healthcare investing, focusing on investing in biotech companies.